Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.
Status:
Recruiting
Trial end date:
2021-05-15
Target enrollment:
Participant gender:
Summary
Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio),
expected to decrease inflammation and expression of adhesion molecules in the endothelium,
leukocyte tissue infiltration and epithelial destruction, and to promote immune tolerance
through a change in the Cytokine balance, which is decisive in preventing multiorgan failure
and death in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6
according to the WHO classification
Phase:
Phase 2
Details
Lead Sponsor:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia